
    
      Patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIB cervical
      cancer are eligible for our study. They will receive cisplatin based neoadjuvant chemotherapy
      (NACT) 3 cycles followed by radical surgery (RS) (type III to V radical hysterectomy plus
      systematic pelvic lymphadenectomy) (arm A) or external beam radiation (EBRT) with concurrent
      weekly platinum 40mg/m2 followed by brachyradiotherapy (arm B).
    
  